Essential Information About Regencell Bioscience (RGC) for Potential Investors

By Ken Smith • Wednesday, July 23 15:20 • Permanent Link

Regencell Bioscience logged a 7.5% change during today's afternoon session, and is now trading at a price of $14.7 per share. The S&P 500 index moved 1.0%. RGC's trading volume is 2,633,603 compared to the stock's average volume of 2,969,167.

If you are considering an investment in RGC, you'll want to know the following:

Regencell Bioscience has moved 3747.9% over the last year, and the S&P 500 logged a change of 16.3%
Based on its trailing earnings per share of -0.01, Regencell Bioscience has a trailing 12 month Price to Earnings (P/E) ratio of -1470.0 while the S&P 500 average is 29.3
Its Price to Book (P/B) ratio is 1049.99 compared to its sector average of 3.19
Regencell Bioscience Holdings Limited operates as a Traditional Chinese medicine (TCM) bioscience company in Hong Kong.
Based in Causeway Bay, the company has 12 full time employees and a market cap of $7.27 Billion.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.